䊋 Parietal lobe:
• Seizures.
• Sight disturbances result in visual field defect.
• Sensory loss: Unable to identify object placed in hand without looking.
䊋 Temporal lobe:
• Seizures
• Taste or smell hallucinations
• Auditory hallucinations
• Depersonalization
• Emotional changes
• Visual field defects
• Receptive aphasia
• Altered perception of music
Test Results
䊋 MRI with gadolinium (contrast) defines tumor location, size.
䊋 CT shows characteristic appearance of meningioma.
䊋 Angiography shows blood flow to the area; some tumors displace ves-
sels as they grow.
Treatment
䊋 Chemotherapeutic agents alone, in combination with radiation and surgery.
May be given orally, intravenously, or through an Ommaya reservoir.
Drugs are chosen based on cell type:
• Carmustine, lomustine, procarbazine, vincristine, temozolomide,
erlotinib, gefitinib
䊋 Irradiation of the area to decrease tumor size.
䊋 Craniotomy to remove the tumor, if appropriate, depends on location,
size, primary site of cancer, and number of tumors. Some patients may
have several small, scattered tumors, making surgery impractical.
䊋 Administer glucocorticoid to reduce swelling or inflammatory response
within confined space inside skull (no room to expand; bone does not give):
• Dexamethasone
䊋 Administer osmotic diuretic to reduce cerebral edema:
• Mannitol
䊋 Administer anticonvulsant to reduce chance of seizure activity:
• Phenytoin, phenobarbital, carbamazepine, divalproex sodium, val-
proic acid, levetiracetam, lamotrigine, clonazepam, topiramate, etho-
suximide
䊋 Administer mucosal barrier fortifier to reduce risk of gastric irritation:
• Sucralfate
䊋 Administer H
2
receptor antagonists to reduce risk of gastric irritation:
• Ranitidine, famotidine, nizatidine, cimetidine
Pediatric Nursing Demystified
216